AstraZeneca's Enhertu Wins China Reimbursement

AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare Security Administration.
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst of an ongoing probe that’s ensnared some of its senior executives.
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance scheme from January 1, as per a recent update from the National
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration. The antibody-drug conjugate,
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added for reimbursement by state-run medical insurance in China,
Targeted Oncology2h
Insights on Tucatinib Regimens in HER2+ Breast Cancer Treatment
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...
devdiscourse1h
Pharma Power: Drug Prices and New Horizons
The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...
pharmaphorum9d
NICE blames companies for breakdown in Enhertu talks
AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...
GlobalData on MSN9d
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
FiercePharma8d
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...
devdiscourse17h
Health News Briefs: Breakthroughs and Controversies
The latest health news includes studies on medications for thyroid issues and breast cancer, the healthcare industry's ...
The Pharma Letter9d
Talks with Enhertu makers end without agreement, says the NICE
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...
FiercePharma10d
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...
BMJ6d
Does NICE’s “severity modifier” for assessing diseases need to change?
Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in England and Wales after negotiations collapsed over pricing. Jacqui Wise examines calls for NICE to ...